Suppr超能文献

透析动静脉内瘘

Dialysis Fistula

作者信息

Marsh Amanda M., Genova Rafaella, Buicko Lopez Jessica L.

机构信息

Florida Atlantic University Schmidt College of Medicine

Univ. Tennessee- St Thomas West

Abstract

Dialysis fistula creation is a commonly performed procedure for patients who suffer from end-stage renal disease (ESRD) who require permanent vascular access in order to receive long-term hemodialysis. The ideal dialysis fistula delivers a high flow rate sufficient for effective dialysis, is suitable for repeated cannulation, and has long-term patency rates with minimal complications. According to the National Kidney Foundation, over 400,000 patients are treated with hemodialysis in the United States with medicare spending, on average, 90,000 USD per patient per year of treatment. While there are various techniques for permanent dialysis access, arteriovenous fistulas (AVFs) are proven to have superior clinical and economic advantages. Guidelines from the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (KDOQI) and the Fistula First Initiative recommend that autogenous AVFs should be considered as the preferred initial access for hemodialysis in patients with ESRD, followed by prosthetic grafts, and finally hemodialysis catheters. Studies have demonstrated a clinically significant decrease in the rate of infections, hospitalizations, catheter failure, central venous stenosis, and mortality, as well as overall cost with AVFs compared to prosthetic grafts or hemodialysis catheters. Despite the prolonged maturation time that delays immediate use, patency rates for AVFs range from 3 to 5 years, compared to 1 to 2 years for AV grafts. This article will discuss the relevant anatomy, indications, contraindications, procedure details, and complications associated with arteriovenous dialysis fistula creation.

摘要

对于终末期肾病(ESRD)患者而言,建立透析动静脉内瘘是一种常见的手术操作,这些患者需要永久性血管通路以接受长期血液透析。理想的透析动静脉内瘘应具备足够高的血流量以确保有效透析,适合反复穿刺,并且长期通畅率高且并发症最少。根据美国国家肾脏基金会的数据,美国有超过40万患者接受血液透析治疗,医疗保险平均每年为每位患者花费9万美元。虽然有多种建立永久性透析通路的技术,但动静脉内瘘(AVF)已被证明具有卓越的临床和经济优势。美国国家肾脏基金会的肾脏病预后质量倡议(KDOQI)和动静脉内瘘优先倡议的指南建议,自体AVF应被视为ESRD患者血液透析的首选初始通路,其次是人工血管移植物,最后是血液透析导管。研究表明,与人工血管移植物或血液透析导管相比,AVF在感染率、住院率、导管失功率、中心静脉狭窄率和死亡率以及总体成本方面均有显著的临床下降。尽管AVF的成熟时间较长,延迟了其立即使用,但AVF的通畅率可达3至5年,而人工血管移植物的通畅率为1至2年。本文将讨论与动静脉透析内瘘建立相关的解剖结构、适应证、禁忌证、手术细节和并发症。

相似文献

9
Patient-centric analysis of dialysis access outcomes.以患者为中心的透析通路结局分析。
J Vasc Access. 2010 Jan-Mar;11(1):31-7. doi: 10.1177/112972981001100107.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验